文献速递糖尿病肥胖与代谢综合征

比利时1型糖尿病患者的代谢健康:一项重复横断面研究

Metabolic health in people living with type 1 diabetes in Belgium: a repeated cross-sectional study.
PubMed 文献 · Diabetologia · 2024-09-13

该研究基于比利时101家糖尿病门诊2001至2022年收集的26791例成人1型糖尿病登记数据,分析20年间治疗与代谢健康演变。结果显示血糖和血脂控制总体改善,但肥胖患病率从2001年12.1%升至2022年21.7%,符合代谢综合征定义的比例大幅上升,且合并代谢异常与眼并发症、周围神经病变、慢性肾脏病和心血管疾病强烈相关。

要点

  • 2001至2022年比利时成人1型糖尿病患者肥胖患病率由12.1%升至21.7%(p<0.0001)。
  • 按WHO标准合并代谢异常者女性由26.9%升至42.9%、男性由30.4%升至52.1%(p<0.0001)。
  • 合并代谢异常者糖化血红蛋白>58 mmol比例更高,且更常使用二甲双胍、SGLT2抑制剂和GLP-1受体激动剂等辅助治疗。

核心结论

  • 过去20年比利时1型糖尿病患者超重、肥胖和合并代谢异常日益增多,进一步加速微血管和大血管并发症风险。
  • 作者认为早期识别合并代谢异常应使治疗干预转向多因素综合管理,在严格血糖控制基础上重视避免超重的教育(如饮食咨询)并加强降压药和他汀类药物的使用。
  • 作者认为应更深入探索将辅助治疗作为该人群降低并发症风险的工具。

研究设计与样本

  • 基于比利时健康保险系统强制实施的糖尿病质量改进与流行病学项目,系统收集2001至2022年全部101家糖尿病门诊接受强化胰岛素治疗患者的数据。
  • 分析对象为年龄≥16岁、诊断年龄≤45岁且糖尿病病程≥1年的成人1型糖尿病患者。
  • 最终数据集包含2001至2022年间收集的26791条成人1型糖尿病登记记录。
  • 分析糖化血红蛋白、BMI、LDL胆固醇、收缩压、降脂治疗和降压治疗随时间的演变,并在2022年数据中分析合并代谢异常与代谢健康指标、并发症及治疗的关系。

主要发现

  • 肥胖患病率由2001年12.1%升至2022年21.7%(p<0.0001)。
  • 按WHO标准合并代谢异常女性由2001年26.9%升至2022年42.9%(p<0.0001),男性由2001年30.4%升至2022年52.1%(p<0.0001)。
  • 按不含白蛋白尿的WHO标准,女性由2001年22.3%升至2022年40.6%(p<0.0001),男性由2001年25.1%升至2022年49.2%(p<0.0001)。
  • 按NCEP-ATPIII标准,女性由2005年39.9%升至2022年57.2%(p<0.0001),男性由2005年40.8%升至2022年60.9%(p<0.0001);按IDF标准,女性由2005年43.9%升至2022年59.3%(p<0.001),男性由2005年33.7%升至2022年50.0%(p<0.0001)。
  • 合并代谢异常者较无合并代谢异常者血糖更高:男性糖化血红蛋白>58 mmol者48.9% vs 36.9%,女性53.3% vs 41.1%(p<0.0001)。

关键数值与推荐

  • 合并代谢异常的定义采用WHO标准、不含白蛋白尿的WHO标准、NCEP-ATPIII标准和IDF标准。
  • 合并代谢异常者更常接受二甲双胍、钠-葡萄糖转运蛋白2抑制剂和胰高血糖素样肽-1受体激动剂等辅助治疗。
  • 校正年龄、糖尿病病程和糖化血红蛋白后,男性和女性中合并代谢异常均与眼并发症、周围神经病变、慢性肾脏病和心血管疾病的存在强烈相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Metabolic abnormalities such as central obesity, insulin resistance, dyslipidaemia and hypertension, often referred to as 'the metabolic syndrome' (or 'combined metabolic abnormalities'), are increasingly being identified in people living with type 1 diabetes, accelerating the risk for CVD. As a result, in recent years, treatment in people living with type 1 diabetes has shifted to improving overall metabolic health rather than glucose control alone. In Belgium, diabetes care for people living with type 1 diabetes is centrally organised. The Initiative for Quality Improvement and Epidemiology in Diabetes, imposed by the Belgian health insurance system, has systematically collected data from patients on intensive insulin therapy treated in all 101 diabetes clinics in Belgium since 2001. The aim of this real-world study is to describe the evolution of treatment and metabolic health, including the prevalence of obesity and combined metabolic abnormalities, in people living with type 1 diabetes over the past 20 years, and to compare the treatment and prevalence of complications between those with and without combined metabolic abnormalities. METHODS: We analysed data on adults (≥16 years old) living with type 1 diabetes, who were diagnosed at age ≤45 years and who had a diabetes duration ≥1 year, collected between 2001 and 2022. The evolution of HbA1c, BMI, LDL-cholesterol, systolic BP, lipid-lowering therapy and antihypertensive therapy over time was analysed. The prevalence of individual and multiple metabolic abnormalities according to various definitions of the metabolic syndrome/combined metabolic abnormalities was analysed, and the association between combined metabolic abnormalities and metabolic health indicators, complications and treatment was investigated in the 2022 data. RESULTS: The final dataset consisted of 26,791 registrations of adults living with type 1 diabetes collected between 2001 and 2022. Although glycaemic and lipid control generally improved over time, the prevalence of obesity strongly increased (12.1% in 2001 vs 21.7% in 2022, p<0.0001), as did the presence of combined metabolic abnormalities (WHO criteria: 26.9% in 2001 vs 42.9% in 2022 in women, p<0.0001; 30.4% in 2001 vs 52.1% in 2022 in men, p<0.0001; WHO criteria without albuminuria: 22.3% in 2001 vs 40.6% in 2022 in women, p<0.0001; 25.1% in 2001 vs 49.2% in 2022 in men, p<0.0001; NCEP-ATPIII criteria: 39.9% in 2005 vs 57.2% in 2022 in women, p<0.0001; 40.8% in 2005 vs 60.9% in 2022 in men, p<0.0001; IDF criteria: 43.9% in 2005 vs 59.3% in 2022 in women, p<0.001; 33.7% in 2005 vs 50.0% in 2022 in men, p<0.0001). People with combined metabolic abnormalities had higher glucose levels compared to those without combined metabolic abnormalities (HbA1c >58 mmol in men: 48.9% vs 36.9%; HbA1c >58 mmol in women: 53.3% vs 41.1%, p<0.0001). People with combined metabolic abnormalities were more often treated with adjunct therapies such as metformin, sodium-glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists. In both men and women, the presence of combined metabolic abnormalities was strongly related to the presence of eye complications, peripheral neuropathy, chronic kidney disease and CVD, corrected for age, diabetes duration and HbA1c. CONCLUSIONS/INTERPRETATION: Overweight, obesity and combined metabolic abnormalities are increasingly being identified in people living with type 1 diabetes, further accelerating the risk of microvascular and macrovascular complications. Early identification of the presence of combined metabolic abnormalities should enable therapeutic interventions to be modified towards multifactorial approaches, with attention to education on avoidance of overweight (e.g. dietary counselling) in addition to strict glycaemic control and intensification of use of antihypertensive agents and statins. Use of adjunct therapies in this population as a tool should be explored more thoroughly to reduce risk of complications.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Lavens A, De Block C, Oriot P, et al. Metabolic health in people living with type 1 diabetes in Belgium: a repeated cross-sectional study. Diabetologia. 2024. PMID: 39271516. doi:10.1007/s00125-024-06273-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。